SOLASTO CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 495 JPY | 0.00% |
|
+0.20% | -19.64% |
| Apr. 22 | Solasto's Occupancy Rate Slips in March | MT |
| Mar. 21 | Solasto's Number of Facility Residents Up Nearly 14.7% in February | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 8.87 for the current year.
- The stock, which is currently worth 2024 to 0.42 times its sales, is clearly overvalued in comparison with peers.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -19.64% | 297M | - | ||
| +14.10% | 81.68B | C+ | ||
| -30.15% | 69.23B | B- | ||
| +9.37% | 29.08B | C+ | ||
| -11.90% | 16.88B | B | ||
| -0.36% | 16.85B | A- | ||
| -1.12% | 15.15B | A- | ||
| +5.90% | 12.62B | A- | ||
| +35.78% | 12.47B | B- | ||
| -4.20% | 11.66B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 6197 Stock
- Ratings Solasto Corporation
